Sharekhan's research report on Biocon
Q3FY2021 was a weak quarter as COVID-19 disruptions led to procurement and supply chain delays, and also affected Biocon’s planned market expansion initiatives. Biocon sees this as a short-lived phenomenon and expects businesses to regain normalcy by FY2022. Biologics segment is expected to be a critical growth driver and the company is well placed to harness the growth opportunities. Better growth prospects, healthy balance sheet and lower debt-equity augur well for company. Possible listing of subsidiary – Biocon Biologics points towards significant value unlocking potential.
Outlook
We retain a Buy on Biocon Limited with a revised PT of Rs. 470.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
